NAS:ACHV (USA) Also trade in: Germany

Achieve Life Sciences Inc

$ 2.09 -0.02 (-0.95%)
Volume: 78,983 Avg Vol (1m): 281,313
Market Cap $: 16.67 Mil Enterprise Value $: 7.05 Mil
P/E (TTM): 0.00 P/B: 1.38
Earnings Power Value -4.61
Net Current Asset Value 0.93
Tangible Book 1.03
Projected FCF -27.21
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 241.63
Cash-To-Debt ranked higher than
97.96% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ACHV: 241.63
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 43.54, Max: 10000
Current: 241.63
0.02
10000
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.50
DISTRESS
GREY
SAFE
Beneish M-Score 1.80
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -1312.02%
WACC 18.18%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -124.08
ROE ranked lower than
83.82% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ACHV: -124.08
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -249.33, Med: -45.23, Max: -6.49
Current: -124.08
-249.33
-6.49
ROA % -99.28
ROA ranked lower than
90.31% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ACHV: -99.28
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -154.51, Med: -28.74, Max: -3.98
Current: -99.28
-154.51
-3.98
ROC (Joel Greenblatt) % -38016.91
ROC (Joel Greenblatt) ranked lower than
87.16% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ACHV: -38016.91
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -38016.91, Med: -7628.08, Max: 2360.34
Current: -38016.91
-38016.91
2360.34
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate ranked lower than
90.32% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ACHV: -100
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -48.5, Max: 635.6
Current: -100
0
635.6
3-Year Total EBITDA Growth Rate 12.20
3-Year EBITDA Growth Rate ranked higher than
95.39% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ACHV: 64.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -19.2, Max: 77.5
Current: 64.2
0
77.5
3-Year EPS w/o NRI Growth Rate 62.80
3-Year EPS w/o NRI Growth Rate ranked higher than
88.60% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ACHV: 62.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -3.7, Max: 73
Current: 62.8
0
73

» ACHV's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ACHV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325413    SIC : 2835
Compare NAS:VICL ASX:EX1 OTCPK:RGRX OTCPK:CAPD OTCPK:ZCOR LSE:SCLP NZSE:BLT OSTO:PROMO NGM:GTAB B LSE:HVO ROCO:4195 TSX:MBX ASX:IVQ NAS:CNAT OTCPK:ETST NAS:HTBX XPAR:LYS NAS:GNPX TSXV:NVH XKRX:216400
Traded in other countries SP4N.Germany
Address 19820 North Creek Parkway, Bothell, WA, USA, 98011
Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next-generation cancer therapeutics. The company's product candidate is apatorsen which is designed to block the production of heat shock protein 27, or Hsp27, a protein that promotes treatment resistance in cancer. The group has business offices located in Bothell, Washington and Vancouver, British Columbia.

Ratios

Current vs industry vs history
PB Ratio 1.38
PB Ratio ranked higher than
97.09% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ACHV: 1.38
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.02, Med: 2.12, Max: 34.09
Current: 1.38
0.02
34.09
EV-to-EBIT -0.44
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ACHV: -0.44
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -7.4, Med: 0.1, Max: 309.9
Current: -0.44
-7.4
309.9
EV-to-EBITDA -0.44
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ACHV: -0.44
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -7.9, Med: 0.1, Max: 266
Current: -0.44
-7.9
266
Current Ratio 2.63
Current Ratio ranked lower than
75.33% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ACHV: 2.63
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 3.43, Max: 18.91
Current: 2.63
0.01
18.91
Quick Ratio 2.63
Quick Ratio ranked lower than
70.95% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ACHV: 2.63
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 3.43, Max: 18.91
Current: 2.63
0.01
18.91

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -135.10
3-Year Share Buyback Rate ranked lower than
91.25% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ACHV: -135.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -135.1, Med: -26.8, Max: 0
Current: -135.1
-135.1
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.07
Price-to-Tangible-Book ranked higher than
88.26% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ACHV: 2.07
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.51, Med: 3.66, Max: 30.56
Current: 2.07
0.51
30.56
Earnings Yield (Joel Greenblatt) % -224.31
Earnings Yield (Greenblatt) ranked lower than
94.54% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ACHV: -224.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7538.7, Med: 0.4, Max: 15309.7
Current: -224.31
-7538.7
15309.7

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N